Wanjia Group Holdings Limited Overview
Wanjia Group is a micro-cap, Hong Kong-listed healthcare holding company whose entire revenue (HK$165.4 million in FY2026) is earned in mainland China from two businesses: a provincial pharmaceutical wholesale and distribution operation in Fujian (HK$55.3 million, 33% of revenue) and a chain of self-operated hemodialysis treatment centres in Guangdong plus related consultancy services (HK$110.1 million, 67%). The company is the much-shrunken remnant of a Fujian pharmaceutical wholesaler and retail-pharmacy operator whose revenue exceeded HK$2.0 billion in FY2014 before provincial procurement reforms eroded the distribution franchise. Since 2020 management, led by CEO Wang Jia Jun, has repositioned the group around chronic renal care, but execution has been undermined by repeated goodwill impairments (HK$46.6 million in FY2022; HK$22.3 million in FY2024), medical-insurance reimbursement clawbacks and claim suspensions. The group has reported losses in four of the last five fiscal years and recapitalised through a HK$44.8 million rights issue completed in April 2026.
The company's own description
In its FY2026 annual results announcement (29 June 2026), the company describes itself as an investment holding company whose subsidiaries are principally engaged in pharmaceutical wholesale and distribution and in hemodialysis treatment and consultancy services in the PRC. It states that the pharmaceutical business serves a broad customer base through its distribution network in Fujian Province, with customers grouped into hospitals and healthcare institutions, and end customers such as pharmacy retail chains, independent pharmacies, community-hospital outpatient departments, healthcare service stations and clinics. For hemodialysis, it states that it operates several self-operated treatment centres across Guangdong Province. Management summarised FY2026 as a year of streamlining PRC operations to control costs, tightening cash-flow management and adopting a more prudent approach to expansion.
Business model and revenue model
| Dimension | Pharmaceutical wholesale & distribution | Hemodialysis treatment & consultancy |
|---|---|---|
| FY2026 revenue (HK$ M) | 55.321 | 110.064 |
| Share of group revenue (FY2026) | 33.5% | 66.5% |
| Revenue type | Product sales (traded goods) | Healthcare services (per-session treatment fees, largely reimbursed by PRC basic medical insurance) plus consultancy fees to hospitals |
| Revenue recognition (per filings) | At a point in time; contracts one year or less | At a point in time; contracts one year or less |
| Geography | Fujian Province | Guangdong Province (historically also Fujian via a jointly operated centre) |
| Customer credit terms | 30–90 days | 5–365 days |
| Key payer | Hospitals, pharmacies, clinics | County/municipal medical insurance (security) bureaux; patients |
| FY2026 segment result (HK$ M) | -0.293 | 3.066 |
There is no subscription or licensing revenue. The mix is approximately one-third product distribution and two-thirds service. All revenue is from external customers in the PRC; no inter-segment sales occurred in FY2025 or FY2026. No single customer exceeded 10% of revenue in FY2024, FY2025 or FY2026; in FY2023 one pharmaceutical customer contributed HK$18.553 million (10.7%), and in FY2022 one customer contributed HK$17.191 million (11.1%).
Value-chain position
Pharmaceutical distribution: mid-stream, provincial-level wholesaler buying from manufacturers/upstream distributors and reselling to hospitals and retail outlets. It is a price-taker squeezed between manufacturers and centrally procured hospital pricing. Segment gross economics are thin and the segment has been loss-making at the segment-result level in each of FY2023–FY2026.
Hemodialysis: downstream provider of chronic, recurring (typically two to three sessions per week) maintenance dialysis to end-stage renal disease patients through standalone outpatient centres, with reimbursement exposure to local medical insurance bureaux. Consultancy services involve supplying equipment, trained staff and operating know-how to hospitals (e.g., the 10-year service contract signed in March 2020 with Zhuhai Jiulong Hospital, disclosed in the FY2022 results).
Independent characterisation
Wanjia is best understood as a sub-scale, regionally concentrated renal-care operator with a legacy distribution tail. Its economics are dominated by: (i) reimbursement policy at county level in Guangdong, which has repeatedly reached back to claw back fees (approx. HK$6 million covering 2020–2023, settled in FY2024; a further refund request for 2021–2024 that drove the FY2025 loss; and a 61-day claim-submission suspension at a Wuhua County centre in November–December 2025 costing an estimated HK$4 million); (ii) licensing and community-acceptance risk on new centres (Huidong never obtained its specialty licence and was sold; Maoming was blocked by villager opposition); and (iii) corporate overhead (unallocated corporate costs of HK$10.6 million in FY2026) that is large relative to segment profit (HK$2.8 million). The group lacks the capital to scale, which explains repeated equity raises (placings in October 2018 and August–September 2019, a 2-for-1 rights issue in 2020 and a 1-for-1 rights issue in 2026).
Strategy
Stated strategy (themes from FY2022–FY2026 annual results and reports)
-
Centralise resources on hemodialysis. Since FY2022 the company has repeatedly stated it will concentrate on hemodialysis treatment and consultancy, growing through new self-operated centres, consultancy services to hospitals, and acquisitions, citing unmet PRC demand.
-
Streamline and control costs. FY2024, FY2025 and FY2026 MD&A describe streamlining PRC operations, effective cash-flow management, and a more prudent approach to expansion.
-
Compliance strengthening. After the reimbursement refunds, the company stated (June 2025 profit warning) that additional staff were deployed to ensure adherence to medical-insurance rules.
-
Opportunistic healthcare investment. Rights-issue use of proceeds reserves funds for "potential investment opportunities related to medical and healthcare fields".
-
Shareholder value. Generic commitment to long-term value creation; no dividend since at least FY2021.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Targets / status |
|---|---|---|---|
| 1-for-1 rights issue | Announced 30 Dec 2025; completed 1 Apr 2026 | 560,222,136 rights shares at HK$0.08; gross approx. HK$44.82m, net approx. HK$40.82m; non-underwritten; Kingkey Securities as placing agent for unsubscribed shares | Use: HK$17.32m business development/healthcare investments; HK$13.5m to settle approx. HK$5.0m payables and approx. HK$8.5m director loan plus interest; HK$10.0m working capital. None utilised as at 31 Mar 2026 |
| Authorised capital increase | Effective 11 Feb 2026 | HK$50m (1bn shares) to HK$100m (2bn shares), par HK$0.05 | Completed |
| Compliance remediation in hemodialysis | 2023–2026 | Extra compliance staff; resumption of Wuhua claims from 1 Jan 2026 | Ongoing |
| Cost rationalisation | FY2025–FY2026 | Admin expenses cut from HK$23.7m to HK$19.9m; S&D cut from HK$32.0m to HK$30.7m | No quantified target |
| Board refresh / diversity | Sep 2024 – Mar 2026 | Two female INEDs and a fourth INED added | Achieved |
| General mandates | 11 Sep 2026 AGM | Issue mandate and buy-back mandate (up to 10% of issued capital) | Approved per AGM results headline |
Medium-term targets and guidance
The company has not published medium-term financial targets or numerical guidance. The FY2025 results contained no outlook guidance (per Reuters/PUBT brief), and the FY2026 results reiterate qualitative commitments only. No sustainability-linked targets or quantified ESG commitments have been identified.
Products & Services
The company does not publish a product catalogue, brand list or price list in its results announcements. The catalog below reflects every offering that can be identified from public filings; items not disclosed are flagged.
Pharmaceutical wholesale & distribution (Fujian)
| Offering | Description | Target customer | Launch / latest | Pricing model | Flagship / named products |
|---|---|---|---|---|---|
| Hospital distribution | Wholesale supply of pharmaceutical and related products to public and private hospitals and healthcare institutions in Fujian | Hospitals, healthcare institutions | Since pre-IPO era (business founded 2004 per aggregators) | Distribution margin on procured drugs; hospital pricing constrained by Fujian medical reform and procurement rules | — |
| Retail/primary-care channel distribution | Supply to pharmacy chains, independent pharmacies, community-hospital outpatient departments, healthcare service stations and clinics | Pharmacies, primary-care outlets | Ongoing | Trade pricing; 30–90 day credit | — |
| Medical supplies | The FY2026 interim report referenced lower demand for certain medical supplies in H1 FY2026, implying medical consumables are distributed alongside drugs | Hospitals, clinics | Ongoing | — | — |
| Legacy retail pharmacy chain (historical) | Fujian Huihao Sihai Pharmaceutical Chain retail outlets (approx. 100 stores at listing) | Consumers | 2013-era | Retail | Not current; status of chain not disclosed in recent filings |
Hemodialysis treatment & consultancy (Guangdong; formerly Fujian)
| Offering | Description | Target customer | Launch / status | Pricing model | Named sites |
|---|---|---|---|---|---|
| Self-operated hemodialysis centres | Standalone maintenance hemodialysis treatment centres; "several" centres across Guangdong (exact count not disclosed in FY2024–FY2026 results) | End-stage renal disease patients; payer is local basic medical insurance | Operating; one centre's claims tied to Wuhua County Medical Insurance Management Centre (Meizhou area) | Per-session fees subject to county-level caps and medical-insurance claims; credit terms 5–365 days | Wuhua-linked centre (name not disclosed); other Guangdong centres not named |
| Ancillary services within treatment | Ancillary items/services charged alongside dialysis (the subject of the 2023 and 2025 refund demands) | Patients / insurers | Under tighter compliance since 2023; extra compliance staff deployed (June 2025 profit warning) | Per-item charges, subject to bureau review | — |
| Hemodialysis consultancy service | Provision of equipment, trained staff and operational know-how to hospitals running dialysis units | Hospitals | 10-year contract with Zhuhai Jiulong Hospital signed March 2020 | Service fees (terms not disclosed) | Zhuhai Jiulong Hospital (珠海九龍醫院有限公司) |
| Jointly operated centre (suspended) | Xianyou Centre in Xianyou Boai Hospital, Fujian; Lianan supplied equipment and staff for a 50% profit share | Patients via JV | Agreement April 2014; cooperation halted January 2022 pending litigation | Profit share | Xianyou Centre (Fujian) |
| Pipeline centre — Maoming | Self-operated centre in Maoming, Guangdong; renovation mostly complete; licence held up by villager opposition | Patients | In 2022, management expected opening only in 2026; current status not disclosed in FY2026 results | — | Maoming Centre |
| New centre planned (FY2024 disclosure) | Additional centre in Guangdong expected to open in 2025, requiring capital investment (cited in FY2024 goodwill impairment rationale) | Patients | Opening status not confirmed in FY2025/FY2026 results | — | Not named |
| Disposed — Huidong | Self-operated centre in Huidong, Guangdong; trial run 2019–2021, never obtained specialty licence | — | Sold for RMB3.5 million; completed 11 May 2023 | — | Huidong Centre |
Treatment volumes, number of dialysis stations/machines, patient numbers and per-session tariffs are not publicly disclosed in the documents reviewed.
Financial Narrative
Income statement: notes and sources
Notes: FY2025 EPS shown as restated in the FY2026 filing (adjusted weighted shares 693,608,359 for the rights issue); on the original 560,222,136 weighted shares FY2025 basic loss per share was approx. HK1.18 cents (calc.). EBITDA is not reported by the company; it is calculated as operating profit plus depreciation of PPE and right-of-use assets (no amortisation of intangibles disclosed). FY2024 "other loss, net" of HK$1.769 million included a HK$5.030 million loss on PPE disposals offset by a HK$3.009 million gain on disposal of the Huidong subsidiary.
Margins and growth (%)
Revenue CAGR (calc.): FY2022–FY2026 (4 years): +1.7% p.a. FY2021–FY2026 (5 years, base HK$114.086 million): +7.7% p.a., almost entirely from hemodialysis ramp-up in FY2022–FY2023.
Commentary. Revenue growth was strong in FY2022–FY2023 as Guangdong centres ramped up (hemodialysis +87% in FY2022), then stalled. The key inflection is gross margin, which has fallen 8.1 percentage points from 35.0% (FY2022) to 26.9% (FY2026), reflecting county-imposed per-visit fee caps, the loss of high-margin ancillary charges after the 2023 inspection, a growing share of low-margin distribution revenue, and in FY2026 approximately HK$4 million of lost claims in a high-fixed-cost centre. Management has responded with cost control (administrative expenses down 33% from HK$29.8 million in FY2024 to HK$19.9 million in FY2026; S&D down 14% over the same period), but this has not been sufficient to offset gross-profit erosion. Excluding goodwill impairments, the business generated modest positive EBITDA in FY2022, FY2023 and FY2025 and slightly negative EBITDA in FY2024 and FY2026. The derived second-half FY2026 numbers are weak: H2 revenue approx. HK$79.7 million with an attributable loss of approx. HK$9.2 million (calc. from full-year less interim), versus an H1 loss of only HK$0.7 million.
Balance sheet
Notes: FY2023 balance sheet also included assets held for sale of HK$3.703 million and associated liabilities of HK$2.838 million (Huidong). The company's own gearing ratio ((borrowings + director loan + leases − cash) / owners' equity) was 0.15 (FY2022), 0.13 (FY2023) and 0.08 (FY2024), matching the net-debt calculation above. Goodwill cost was HK$923.1 million against accumulated impairment of HK$870.1 million at 31 March 2022 — evidence that historical acquisitions were carried at values vastly above recoverable amounts and have been almost entirely written off.
Commentary. The balance sheet has shrunk by roughly 31% since FY2022 through impairments and depreciation, while liquidity improved: the group moved from net debt of HK$18.7 million to net cash of HK$12.3 million (FY2026), helped by collections in FY2024 and by part of the rights-issue proceeds received before 31 March 2026. Owners' equity rose HK$16.8 million in FY2026 despite a HK$5.6 million total comprehensive loss attributable to owners, implying approx. A concern is the FY2026 working-capital build: net trade receivables more than doubled to HK$32.1 million (gross receivables aged 91–180 days rose from HK$2.8 million to HK$10.0 million) and trade payables nearly tripled to HK$19.0 million, with HK$4.3 million aged 181–365 days. The remaining HK$8.55 million director loan was earmarked for repayment from rights proceeds.
Cash flow
Operating cash flow, true cash capex and free cash flow are not publicly disclosed in the results announcements reviewed (the full cash-flow statement appears only in the annual reports, which were not accessed). The capex proxy includes non-cash right-of-use additions and therefore overstates cash capex in years with new leases. Management attributed the FY2022 cash decline to repayment of shareholder and director loans, the FY2024 increase to improved receivable collection, and the FY2026 increase to receipt of part of the rights-issue proceeds; interim cash at 30 September 2025 was HK$18.9 million, i.e., cash fell in H1 FY2026 before the rights inflow.
Ratios (calc.)
Net debt/EBITDA: FY2023 0.93x (net debt HK$15.3 million / EBITDA HK$16.4 million); FY2025 the group was in net cash; in FY2022, FY2024 and FY2026 EBITDA was negative on a reported basis, so the ratio is not meaningful.
Commentary. Returns have been negative in four of five years. Interest burden is small in absolute terms (finance costs HK$1.0 million in FY2026, mostly lease interest and interest on the director loan), so the issue is operating profitability rather than leverage. Asset turnover has risen mechanically because the asset base was written down. Receivable days nearly doubled in FY2026, which, combined with the claim suspension, warrants scrutiny of collectability (ECL allowance on trade receivables HK$11.2 million at 31 March 2026).
Interim snapshot — six months ended 30 September 2025 (H1 FY2026)
Source: interim results announcement (reported by Bulletin Express/Tiger, 25 November 2025). Derived H2 FY2026: hemodialysis revenue approx. HK$50.0 million (approx. -8.7% vs derived H2 FY2025 of HK$54.7 million) reflecting the Wuhua suspension; pharmaceutical revenue approx. HK$29.7 million (approx. +27.7%).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Pharmaceutical wholesale & distribution revenue (HKD Mn) | 51.183 | 52.278 | 51.536 | 50.491 | 55.321 |
Hemodialysis treatment & consultancy revenue (HKD Mn) | 103.640 | 121.424 | 129.556 | 111.202 | 110.064 |
Total revenue (HKD Mn) | 154.823 | 173.702 | 181.092 | 161.693 | 165.385 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Pharmaceutical segment result (HKD Mn) | 0.007 | -1.130 | -1.352 | -1.200 | -0.293 |
Hemodialysis segment result, reported (HKD Mn) | -38.014 | 15.450 | -29.538 | 7.357 | 3.066 |
Hemodialysis segment result ex goodwill impairment (HKD Mn, calc.) | 8.616 | 15.450 | -7.228 | 7.357 | 3.066 |
Unallocated corporate income & expenses, net (HKD Mn) | -9.376 | -9.847 | -8.548 | -10.246 | -10.631 |
Group profit/(loss) from operations (HKD Mn) | -47.383 | 4.473 | -39.438 | -4.089 | -7.858 |
Segment Margins & Growth (%)
| Segment | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Pharmaceutical segment margin (%) | 0.0 | -2.2 | -2.6 | -2.4 | -0.5 |
Hemodialysis segment margin, reported (%) | -36.7 | 12.7 | -22.8 | 6.6 | 2.8 |
Hemodialysis margin ex goodwill impairment (%, calc.) | 8.3 | 12.7 | -5.6 | 6.6 | 2.8 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Pharmaceutical revenue growth YoY (%) | -12.9 | 2.1 | -1.4 | -2.0 | 9.6 |
Hemodialysis revenue growth YoY (%) | 87.4 | 17.2 | 6.7 | -14.2 | -1.0 |
Pharmaceutical share of revenue (%) | 33.1 | 30.1 | 28.5 | 31.2 | 33.5 |
Hemodialysis share of revenue (%) | 66.9 | 69.9 | 71.5 | 68.8 | 66.5 |
Segment Assets & Liabilities
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Pharmaceutical segment assets (HKD Mn) | 23.701 | 21.050 | 19.532 | 19.131 | 20.562 |
Hemodialysis segment assets incl. goodwill (HKD Mn) | 165.634 | 147.998 | 95.083 | 84.358 | 83.378 |
Pharmaceutical segment liabilities (HKD Mn) | 8.039 | 7.309 | 7.522 | 8.076 | 8.758 |
Hemodialysis segment liabilities (HKD Mn) | 49.018 | 41.196 | 22.365 | 17.629 | 25.143 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 154.823 | 173.702 | 181.092 | 161.693 | 165.385 |
Cost of sales (HKD Mn) | -100.589 | -116.766 | -126.352 | -111.346 | -120.960 |
Gross profit (HKD Mn) | 54.234 | 56.936 | 54.740 | 50.347 | 44.425 |
ECL (allowance)/reversal, net (HKD Mn) | -3.187 | 7.499 | -4.595 | 1.431 | -1.131 |
Goodwill impairment (HKD Mn) | -46.630 | 0 | -22.310 | 0 | 0 |
Selling & distribution expenses (HKD Mn) | -29.600 | -34.798 | -35.758 | -32.041 | -30.720 |
Administrative expenses (HKD Mn) | -22.250 | -24.584 | -29.789 | -23.745 | -19.866 |
Operating profit/(loss) (HKD Mn) | -47.383 | 4.473 | -39.438 | -4.089 | -7.858 |
Depreciation PPE + ROU (HKD Mn) | 12.743 | 11.923 | 10.413 | 8.219 | 6.581 |
EBITDA, reported basis (HKD Mn, calc.) | -34.640 | 16.396 | -29.025 | 4.130 | -1.277 |
EBITDA ex goodwill impairment (HKD Mn, calc.) | 11.990 | 16.396 | -6.715 | 4.130 | -1.277 |
Finance costs (HKD Mn) | -1.308 | -2.018 | -1.711 | -1.403 | -1.024 |
Pre-tax profit/(loss) (HKD Mn) | -48.691 | 2.455 | -41.149 | -5.492 | -8.882 |
Income tax (HKD Mn) | -2.246 | -0.517 | 0.854 | -1.081 | -1.104 |
Net profit/(loss) for the year (HKD Mn) | -50.937 | 1.938 | -40.295 | -6.573 | -9.986 |
Net profit/(loss) attributable to owners (HKD Mn) | -50.999 | 1.820 | -39.977 | -6.616 | -9.864 |
Basic EPS (HK cents) | -9.10 | 0.32 | -7.14 | -0.95 | -1.38 |
Diluted EPS (HK cents) | -9.10 | 0.32 | -7.14 | -0.95 | -1.38 |
Dividends per share (HK cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 35.7 | 12.2 | 4.3 | -10.7 | 2.3 |
Gross margin (%) | 35.0 | 32.8 | 30.2 | 31.1 | 26.9 |
Operating margin (%) | -30.6 | 2.6 | -21.8 | -2.5 | -4.8 |
EBITDA margin, reported (%) | -22.4 | 9.4 | -16.0 | 2.6 | -0.8 |
EBITDA margin ex impairment (%) | 7.7 | 9.4 | -3.7 | 2.6 | -0.8 |
Net margin, attributable (%) | -32.9 | 1.0 | -22.1 | -4.1 | -6.0 |
S&D expenses / revenue (%) | 19.1 | 20.0 | 19.7 | 19.8 | 18.6 |
Admin expenses / revenue (%) | 14.4 | 14.2 | 16.4 | 14.7 | 12.0 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | 191.818 | 173.448 | 117.101 | 106.822 | 132.579 |
Property, plant & equipment (HKD Mn) | 38.380 | 31.679 | 22.295 | 16.531 | 14.320 |
Right-of-use assets (HKD Mn) | 18.871 | 15.807 | 11.919 | 9.435 | 10.089 |
Goodwill (HKD Mn) | 53.024 | 49.093 | 24.495 | 24.242 | 25.680 |
Other intangibles (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Inventories (HKD Mn) | 14.651 | 12.631 | 7.982 | 10.301 | 12.020 |
Trade & other receivables (HKD Mn) | 61.034 | 50.659 | 32.182 | 22.230 | 37.436 |
Cash & cash equivalents (HKD Mn) | 5.768 | 9.876 | 18.228 | 24.083 | 33.034 |
Trade & other payables (HKD Mn) | 37.730 | 23.897 | 17.742 | 16.460 | 26.491 |
Bank/other borrowings (HKD Mn) | 0 | 7.450 | 1.691 | 0.193 | 0 |
Amount due to a director (HKD Mn) | 3.500 | 0 | 8.450 | 10.000 | 8.550 |
Lease liabilities, total (HKD Mn) | 20.986 | 17.716 | 13.909 | 11.531 | 12.213 |
Short-term debt incl. director loan and current leases (HKD Mn, calc.) | 6.232 | 10.019 | 12.505 | 12.537 | 10.534 |
Long-term debt — non-current leases (HKD Mn) | 18.254 | 15.147 | 11.545 | 9.187 | 10.229 |
Total debt incl. leases (HKD Mn, calc.) | 24.486 | 25.166 | 24.050 | 21.724 | 20.763 |
Net debt / (net cash) (HKD Mn, calc.) | 18.718 | 15.290 | 5.822 | -2.359 | -12.271 |
Total liabilities (HKD Mn) | 63.722 | 53.221 | 41.906 | 38.189 | 47.307 |
Equity attributable to owners (HKD Mn) | 126.179 | 118.197 | 73.488 | 66.882 | 83.653 |
Total equity incl. NCI (HKD Mn) | 128.096 | 120.227 | 75.195 | 68.633 | 85.272 |
Net current assets / working capital (HKD Mn) | 35.985 | 38.795 | 28.031 | 27.612 | 45.412 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Additions to PPE and right-of-use assets — capex proxy (HKD Mn) | 8.053 | 8.113 | 4.026 | 0.831 | 4.153 |
Dividends paid (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Change in cash & equivalents (HKD Mn) | -19.331 | 4.108 | 8.352 | 5.855 | 8.951 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE — attributable NI / avg owners' equity (%) | -34.5 | 1.5 | -41.7 | -9.4 | -13.1 |
ROA — NI / avg total assets (%) | -24.5 | 1.1 | -27.7 | -5.9 | -8.3 |
ROIC — (EBIT − tax) / year-end invested capital (%) | -33.8 | 2.9 | -47.6 | -7.8 | -12.3 |
Current ratio (x) | 1.79 | 2.02 | 1.92 | 1.95 | 2.22 |
Total debt / total equity (x) | 0.19 | 0.21 | 0.32 | 0.32 | 0.24 |
Interest coverage — EBIT / finance costs (x) | -36.2 | 2.2 | -23.0 | -2.9 | -7.7 |
Asset turnover — revenue / avg total assets (x) | 0.75 | 0.95 | 1.25 | 1.44 | 1.38 |
Inventory days (DIO) | 53.2 | 39.5 | 23.1 | 33.8 | 36.3 |
Receivable days (DSO, net trade receivables) | 115.2 | 88.5 | 53.9 | 34.9 | 70.9 |
Payable days (DPO, trade payables) | 117.8 | 53.0 | 30.2 | 22.6 | 57.3 |
Cash conversion cycle (days) | 50.6 | 75.0 | 46.8 | 46.1 | 49.9 |
Income Statement and Margin Analysis (%)
| Metric (HKD Mn unless stated) | H1 FY2025 | H1 FY2026 |
|---|---|---|
Revenue | 83.695 | 85.706 |
Hemodialysis revenue | 56.464 (calc.) | 60.089 |
Pharmaceutical revenue | 27.232 (calc.) | 25.617 |
Gross margin (%) | 31.58 | 30.07 |
Profit/(loss) attributable | 1.256 | -0.712 |
Cash at period end | — | 18.918 |
Current ratio (x) | — | 1.96 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Region
| Region | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Mainland China — total revenue (HKD Mn) | 154.823 | 173.702 | 181.092 | 161.693 | 165.385 |
Hong Kong revenue (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Fujian proxy — pharmaceutical segment (HKD Mn) | 51.183 | 52.278 | 51.536 | 50.491 | 55.321 |
Guangdong proxy — hemodialysis segment (HKD Mn) | 103.640 | 121.424 | 129.556 | 111.202 | 110.064 |
Region Margins & Growth (%)
| Region | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Fujian proxy growth (%) | -12.9 | 2.1 | -1.4 | -2.0 | 9.6 |
Guangdong proxy growth (%) | 87.4 | 17.2 | 6.7 | -14.2 | -1.0 |
Locations
| Location | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Hong Kong non-current assets (HKD Mn) | 1.428 | 2.842 | 3.311 | 2.328 | 2.447 |
Mainland China non-current assets (HKD Mn) | 108.937 | 93.737 | 55.398 | 47.880 | 47.642 |
Data Point Details
| Data point | Value | Source / note |
|---|---|---|
Market capitalisation (17 Oct 2026) | approx. HK$127.5m | TipRanks |
Market capitalisation (early Aug 2026) | approx. HK$134.3m | TipRanks |
Implied share price (Oct 2026) | approx. HK$0.11 | calc. (HK$127.5m / approx. 1,128.6m shares) |
Rights issue subscription price (2026) | HK$0.08 | Prospectus |
CEO open-market purchase (6 Jan 2026) | HK$0.094 | Webb-site |
Pre-rights NAV per share | approx. HK$0.12 | Prospectus summary |
Controlling-stake acquisition price (Dec 2019) | HK$0.192 (pre-2020 consolidation basis) | Webb-site |
3-year total shareholder return (to approx. Aug 2025) | approx. -40% | Simply Wall St |
Valuation Snapshot
| Multiple | Value | Note |
|---|---|---|
EV/Sales | approx. 0.70x | EV approx. HK$115.2m = market cap + total debt HK$20.8m − cash HK$33.0m (pre-full rights proceeds) |
P/S | approx. 0.77x | TipRanks |
P/B | approx. 1.5x | On 31 Mar 2026 owners' equity HK$83.7m; would be lower on a post-rights pro forma basis |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None; no sell-side coverage identified |
Dividend history | No dividends declared for FY2021–FY2026 |
Dividend policy | No formal payout policy disclosed |
Buybacks | None in FY2022–FY2026; general buy-back mandate (up to 10%) sought at 11 Sep 2026 AGM |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | No bank borrowings at 31 Mar 2026; current liabilities include HK$8.55m director loan (earmarked for repayment from rights proceeds) and HK$1.98m current lease liabilities; non-current lease liabilities HK$10.23m |
Transaction by Date
| Date | Transaction | Detail |
|---|---|---|
3 Oct 2018 | Placing (FY19 Placing) | Proceeds used to settle borrowings |
Aug–Sep 2019 | Placing (FY20 Placing) | — |
Jan–Feb 2020 | 2-for-1 rights issue (post share consolidation) | — |
Dec 2025 – Apr 2026 | 1-for-1 rights issue | 560.2m shares at HK$0.08; gross approx. HK$44.82m |
Analyst Conclusions
Management guidance
No numerical guidance has been issued. Management's stated priorities are to deploy rights proceeds into the existing pharmaceutical and hemodialysis businesses and potential healthcare investments, repay the director loan and part of payables, strengthen compliance and continue cost control. There is no consensus estimate for FY2027.
Bull case
-
Clean balance sheet as a platform: with approx. HK$40.8m of net rights proceeds and no bank debt, the group has its strongest liquidity in years; if the Wuhua centre's full-year run-rate is restored (approx. HK$4m of FY2026 lost claims non-recurring), segment profit could rebound toward the FY2025 level (HK$7.4m).
-
Operating leverage on a lean cost base: administrative costs have already been cut by HK$9.9m since FY2024; modest gross-profit recovery would flow through.
-
Structural demand and consolidation optionality: a large, growing dialysis patient pool and small-ticket regional deals could let Wanjia add centres or consultancy contracts cheaply.
Bear case
-
Regulatory pattern, not one-offs: three reimbursement-related hits in three fiscal years (FY2024 refund, FY2025 refund, FY2026 suspension) suggest structurally lower achievable margins; hemodialysis segment margin has fallen from 12.7% to 2.8%.
-
Overhead exceeds segment profit: unallocated corporate costs (HK$10.6m) dwarf segment results (HK$2.8m), so the listed structure destroys value at current scale.
-
Serial dilution and asset quality concerns: a fourth equity raise since 2018, 91.86m options outstanding, FY2026 receivable build, and HK$25.7m remaining goodwill that could be impaired again.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters | Expected timing |
|---|---|---|
| H1 FY2027 interim results | First period with rights proceeds and full Wuhua claims | Late Nov 2026 |
| Use-of-proceeds update | Whether the HK$17.32m development tranche goes to centres, consultancy or M&A | Interim / annual reports |
| Any new reimbursement findings | Recurrence would confirm the bear case | Ongoing |
| Maoming centre / new Guangdong centre status | Only disclosed organic expansion pipeline | Unspecified |
| Receivable collection | Reversal of FY2026 DSO spike (70.9 days) | H1 FY2027 |
| Goodwill impairment test | HK$25.7m at risk if margins stay compressed | FY2027 annual results (Jun 2027) |
| Controlling shareholder actions | Post-rights stake, share pledges, buy-back use | Disclosure of interests filings |
| Xianyou litigation outcome | Potential recovery of profit share | — |
Analyst verdict
Wanjia Group Holdings is a structurally challenged micro-cap whose investment case rests almost entirely on the economics of a handful of Guangdong hemodialysis centres. The data from five years of audited filings tells a consistent story: the dialysis business can grow revenue (from HK$55m in FY2021 to a peak of HK$130m in FY2024) and generate positive pre-impairment segment profit, but it has not been able to protect margins against local reimbursement authorities. Underlying hemodialysis margins have fallen from 12.7% (FY2023) to 2.8% (FY2026), group gross margin is down eight points since FY2022, and corporate overhead consumes more than the operating segments earn. The legacy Fujian distribution business is close to breakeven but offers no strategic moat.
The April 2026 rights issue resolves near-term liquidity: the group now has net cash, no bank debt and the funds to repay its director loan. That materially reduces solvency risk, which had been the dominant concern in FY2022 when cash fell below HK$6 million. However, it does not by itself fix profitability, and the use-of-proceeds plan leaves only about HK$17m for growth — modest relative to the cost of opening and licensing new centres, a process that has already failed twice (Huidong, Maoming).
At roughly 0.7x EV/sales and about 1.5x book on pre-rights equity, the valuation is not demanding in absolute terms, but it is not obviously cheap for a business with negative EBITDA, a history of near-total goodwill write-offs, recurring regulatory clawbacks and a retail-dominated, illiquid register. Absent sell-side coverage or guidance, investors must rely on half-yearly disclosures that omit basic operating KPIs (centre count, patient volumes, tariffs).
Verdict: speculative and high-risk. A constructive view requires evidence, starting with the November 2026 interim, that FY2026's claim suspension was non-recurring, that hemodialysis margins can recover toward high single digits, and that rights proceeds are deployed into accretive capacity. Until then, the balance of evidence favours caution.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / appointment | Committees | Background (where disclosed) |
|---|---|---|---|---|
Mr. Wang Jia Jun (王佳駿) | Executive Director and Chief Executive Officer | Director since 31 Aug 2018; CEO since 1 Apr 2020 (FY2026 filing; FY2022 filing states 1 Apr 2021) | Remuneration Committee member; Nomination & CG Committee member (previously chair) | Joined as Vice President (Project Management) on 1 Aug 2018; bachelor's in business administration, Stony Brook University (2011); master's in health management, Columbia University (2017); prior approx. four years in business analysis and development in major PRC cities (Pharnex biography) |
Dr. Xiao Zhixin | Non-executive Director | On board since at least June 2022 | None disclosed | — |
Dr. Liu Yongping | Independent Non-executive Director | On board since at least June 2021 | Chairman, Remuneration Committee; Chairman, Nomination & CG Committee; member, Audit Committee | — |
Ms. Xu Wei | Independent Non-executive Director | — | Chairwoman, Audit Committee; member of Remuneration and Nomination committees | — |
Ms. Chan Wing Shan Winsome | Independent Non-executive Director | Appointed 13 Sep 2024 | Audit, Remuneration, Nomination committees | — |
Mr. Williamson Lam | Independent Non-executive Director | Appointed 2 Mar 2026 | Audit, Remuneration, Nomination committees | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Attribute | Status |
|---|---|
Board size | 6 (1 ED, 1 NED, 4 INEDs) |
Independence | 4 of 6 (67%) independent |
Gender | 2 of 6 women (33%) — Ms. Xu Wei and Ms. Chan Wing Shan Winsome; the board was all-male (4 members) at June 2024 |
Chair/CEO separation | No chairman since 2014; CEO is the sole executive director — a disclosed deviation from CG Code C.2.1 |
Audit Committee | 4 INEDs; met 3 times in FY2026 |
Remuneration Committee | 4 INEDs + CEO; met 4 times in FY2026; adopts model B.1.2(c)(ii) (recommends to board) |
Nomination & CG Committee | 4 INEDs + CEO; met 3 times in FY2026; Board Diversity Policy adopted |
Listing-rule compliance lapse | INED count fell below three after Ho Man's resignation (30 Apr 2024) until replacement in Sep 2024 |
Directors' Remuneration (Annual)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total directors' emoluments (HKD Mn) | 0 | 2.287 | 2.601 | 2.577 | 2.965 |
Share-based payment expense, group (HKD Mn) | 0.086 | 0.005 | 1.031 | 0.737 | 0 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
30 Apr 2024 | Mr. Ho Man (INED) resigned | Left board below minimum three INEDs |
13 Sep 2024 | Mr. Wong Hon Kit (INED, Audit/Remuneration chair) retired; Ms. Chan Wing Shan Winsome appointed | Restored INED quorum; addressed gender diversity requirement |
2024–2026 | Ms. Xu Wei appointed INED; assumed Audit Committee chair | — |
2 Mar 2026 | Mr. Williamson Lam appointed INED | Board expanded to six |
Major Shareholders
| Holder | Shares | Stake | Notes |
|---|---|---|---|
Power King Investment Development Limited (BVI) / interests of Wang Jia Jun and Yung Ka Lai | 169,555,611 (pre-rights, Mar 2026) | approx. 30.27% (pre-rights) | Webb-site records identical interests for Wang Jia Jun and Yung Ka Lai (joint/attributed interest); CEO bought 520,000 shares at HK$0.094 on 6 Jan 2026; 156.86 million shares were pledged to a lender in April 2020. |
Institutional investors | — | Approx. nil | Simply Wall St (2020) found no institutional ownership; no top-10 institutional register is publicly available for this micro-cap |
Public / retail | — | Majority | Retail-dominated register |
Competitive Landscape
Key Competitors
| Competitor | Type | Relevance | Data point (source) |
|---|---|---|---|
Public hospital nephrology/dialysis units | Public providers | Dominant channel: public hospitals accounted for 84.9% of 7,399 dialysis centres at end-2022 | Chinese Hospital Association Blood Purification Center Branch |
Fresenius Medical Care (FME) | Global integrated dialysis products & services | Built a China clinic/renal-hospital network from 2017–2018 (incl. Guangzhou/Zhaoqing centres via KangNiDaiSi) and later divested six hospital centres to Jiangxi Dakang | FY2025 group revenue EUR19,628m; operating margin 11.3% (FME press release, 24 Feb 2026) |
Jiangxi Dakang Medical Management (DiaCare Medical) | Domestic dialysis chain | Described as China's leading hemodialysis brand with 70+ centres across 15 provinces including Guangdong | ARC Group transaction notes |
Guangdong Kanghua Healthcare (HKEX: 3689) | Guangdong hospital group | Acquired 70% of a haemodialysis outpatient centre operator for RMB7.7m in December 2023 — direct Guangdong competitor | HKEX announcement, 15 Dec 2023 |
Weigao Group (blood purification) | Consumables leader | Leading tubing supplier (approx. 23% share) with downstream blood-purification presence | CHA Blood Purification Branch |
Other private standalone centres | Fragmented local operators | 15.1% of centres were private at end-2022 | CHA Blood Purification Branch |
Key Competitors — Sinopharm Group
| Competitor | Relevance | Data point |
|---|---|---|
Sinopharm Group (HKEX: 1099) | National #1 distributor | 2025 revenue RMB575.168bn (-1.6%); attributable profit RMB7.155bn (2025 annual results, Mar 2026) |
China National Accord Medicines (Sinopharm Accord) | Sinopharm subsidiary, South China distribution/retail | 2025 revenue RMB73.42bn (preliminary) |
China Resources Pharmaceutical (HKEX: 3320) | National distributor | — |
Shanghai Pharmaceuticals (HKEX: 2607) | National distributor | — |
Jointown Pharmaceutical (SSE: 600998) | National distributor | — |
Local Fujian wholesalers | Provincial competitors after the 2019 reform removed the 10-distributor essential-medicine restriction | — |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Wanjia (FY2026, YE Mar 2026) | Sinopharm (FY2025, YE Dec 2025) | Fresenius Medical Care (FY2025) |
|---|---|---|---|
Revenue | HK$165.4m | RMB575.2bn | EUR19.6bn |
Revenue growth | +2.3% | -1.6% | +2% reported (+8% organic) |
Gross margin | 26.9% | — | — |
Operating margin | -4.8% | — | 11.3% (ex special items) |
Net margin | -6.0% (attributable) | approx. 1.2% (calc., attributable) | — |
R&D intensity | Not disclosed (nil line item) | — | — |
